Introduction
Signal transduction initiated by the interactions of hematopoietic growth factors/cytokines with specific receptors is critical for regulating normal hematopoietic cell growth and differentiation. [1] [2] [3] Several of the hematopoietic growth factors utilize members of the type III RTK family. This family is characterized by five immunoglobulin-like folds in the extracellular domain, a single transmembrane domain and an interrupted tyrosine kinase domain in the intracellular region. 4, 5 Members of this receptor family include two receptors which play important roles in hematopoiesis, c-KIT and c-FMS, two receptors for PDGF, and FLT3, the most recently discovered member of this family. 6 During normal hematopoiesis, FLT3 is primarily expressed within the CD34 + hematopoietic stem/progenitor cell fraction as well as a specific population of CD34 − cells. 7 -10 FLT3 appears to play a role in the maintenance of pluripotent hematopoietic stem cells 7, 11, 12 and development of B cell progenitors, [13] [14] [15] and dendritic cells. 11, [16] [17] [18] Similar to other class III RTKs, FLT3 is activated by ligand (FLT3 ligand, FL)-dependent dimerization and transphosphorylation of tyrosine residues. 19, 20 Subsequent signal transduction is mediated through association and/or phosphorylation of cytoplasmic substrates including the p85 subunit of phosphatidylinositol 3Ј-kinase (PI3K), RAS/GTPase activating protein, phospholipase C-␥, VAV, SHC, GRB2 and CBL. [21] [22] [23] [24] [25] [26] [27] c-FMS and c-KIT are over-expressed by many cases of myeloid leukemia but not often in ALL. In contrast, data from our previous studies and others have demonstrated aberrant expression of FLT3 in most cases of B-lineage ALL and AML as well as subsets of T-ALL and CML samples. [28] [29] [30] [31] Overexpression occurs at both RNA and protein levels and leads to a functional receptor as addition of FL in vitro causes phosphorylation of the receptor and a proliferative response in some cases of leukemic cells. 28, 32, 33 Expression of mRNA for the FLT3 ligand (FL) has also been detected in virtually all leukemic-derived cell lines, bone marrow stroma and endothelial cells. 9, [34] [35] [36] Coexpression of SCF/c-KIT and CSF-1/c-FMS pairs has also been reported in cases of leukemia. [37] [38] [39] Coexpression of both FLT3 and its ligand by the same leukemia cell suggest a possible autocrine/paracrine/intracrine signaling loop which could contribute to the development or maintenance of leukemia. 40, 41 In addition, small internal tandem duplications in the juxtamembrane portion of the receptor have been discovered in approximately 20% of patients with AML. [42] [43] [44] [45] The mutation appears to activate the kinase domain of the receptor through constitutive dimerization. 46 While the consequence of FLT3 activation is unproven, it is conceivable that constitutively activated FLT3 plays a role in the proliferation and block in differentiation that characterizes leukemia.
In this report, we model an activated FLT3 receptor to study its possible role in leukemia. Our approach was to generate a constitutively activated FLT3 receptor by fusion of the entire cytoplasmic domain of FLT3 to the helix-loop-helix (HLH; also called 'pointed') domain of TEL. TEL is a member of the ETS family of transcription factors, and contains a highly conserved amino-terminal HLH domain which functions to mediate protein-protein interaction. 47, 48 TEL is notable for its involvement in several chromosomal translocations which result in the generation of chimeric proteins such as TEL-PDGF␤R in CMML, TEL-ABL in AML and TEL-JAK2 in ALL. 49, 50 All of these fusions resulted in activated tyrosine kinase domains and cause transformation when expressed in hematopoietic cells.
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Materials and methods
Construction of chimeric receptors
The construction of the TEL-FLT3 fusions was performed by polymerase chain reaction (PCR) as illustrated in Figure 1a . To generate DNA for the HLH domain of TEL, total RNA from K562 cells was reverse transcribed and the resulting cDNA was used as a template for 35 cycles of PCR: 94°C, 50°C and 72°C (1 min each) using Taq polymerase (GIBCO, Gaithers- (a) Schematic illustration of the construction of TEL-FLT3 and kinase deletion mutant FLT3 (del) and TEL-FLT3 (del) constructs. (b) Oligomerization of TEL-FLT3 in vitro. TEL-FLT3 and TEL-FLT3 (del) cDNA constructs were expressed either alone or together by in vitro transcription and translation using radiolabeled 35 S methionine. Labeled lysates were immunoprecipitated with anti-FLT3 antibody specific for the carboxyl-terminal of FLT3 (lanes 4-6) or with rabbit IgG as a control (lanes 7-9). Total reaction mixtures (lanes 1-3) and immunoprecipitates (lanes 4-9) were resolved by SDS-PAGE, transferred to a membrane, and exposed to film. T/F: TEL-FLT3; T/F (d): TEL-FLT3 (del).
burg, MD, USA) with a primer (P1) containing a Sal1 site and TEL 5Ј sequences: 5Ј-TGATCTCTCTCGCTGTGA-3Ј and a primer (P2) containing sequences for both TEL and FLT3: 5Ј-CTTTTTGTACTTGTGACA (TEL)-TTCTTCATGGTTCTGATG (FLT3)-3Ј. 7, 49 To generate the cytoplasmic domain of FLT3, FLT3 plasmid DNA was amplified by PCR for 30 cycles: 94°C, 55°C and 72°C (1 min each) with a 5Ј primer (P3) containing both TEL and FLT3 sequences: 5Ј-CATCAGAACCATGAAGAA (TEL)-TGTCACAAGTACAAAAAG (FLT3)-3Ј and a 3Ј primer Leukemia (P4) containing FLT3 3Ј sequences: 5Ј-AGCTGTTGCGTTCAT-CAC-3Ј. The resulting TEL and FLT3 PCR products were mixed, boiled, allowed to reanneal and used as templates in a second round of PCR using the P1 and the P4 primers for 30 cycles of amplification: 94°C (1 minute), 50°C (1 min) and 72°C (2 min). The TEL-FLT3 fusion product was digested with Sal1 and BstEII and ligated to the Sal1 and BstEII digested fulllength FLT3 cDNA. The chimeric Tel-FLT3 product was then subcloned into the pCIneo expression vector (Promega, Madi-son, WI, USA). Partial kinase domain deletion mutants for both native FLT3 (FLT3 (del)) and chimeric TEL-FLT3 (Tel-FLT3 (del)) were created by digesting each plasmid with EcoR1 to remove the region coding for the C-terminal 233 amino acids of the kinase domain. The sequences of the recombinant constructs were confirmed by the dideoxy sequencing method.
Cytokines and antibodies
Recombinant murine IL-3 (IL-3) and recombinant human FLT3 ligand were purchased from R & D Systems (Minneapolis, MN, USA). Rabbit polyclonal antibodies against JAK 1, JAK 2, JAK 3, STAT 1, STAT 3, STAT 5a, STAT 5b, and CBL were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,USA). Polyclonal antibodies raised against the carboxyl terminus (amino acids 974-993, C-20) and the kinase insert region (amino acids 740-757, S-18) of FLT3 were from Santa Cruz Biotechnology. Mouse monoclonal antibody against phosphotyrosine (4G10) was purchased from Upstate Biotechnology (UBI, Lake Placid, NY, USA). Rabbit IgG was from Zymed (San Francisco, CA, USA).
In vitro transcription/translation and oligomerization assay
The cDNA constructs encoding TEL-FLT3 and TEL-FLT3 (del) were expressed using an in vitro transcription and translation rabbit reticulocyte lysate kit (TNT; Promega). Proteins were labeled by 35 S methionine (Amersham, Arlington Heights, IL, USA) incorporation. Labeled lysate (20 l) was diluted in NP-40 lysis buffer (20 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 100 mmol/l NaF, 10% glycerol, 1% NP-40 and 10 mmol/l EDTA) and immunoprecipitated with 1 g of anti-FLT3 antibody (C-20) which is specific for the carboxyl-terminal domain of the FLT3. Immunoprecipitates and 5 l of total reaction mixtures were boiled in sample buffer and resolved by SDS-polyacrylamide gel electrophoresis (PAGE). The proteins were transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA) and analyzed by autoradiography.
In vitro kinase assay
Expression of the constructs was carried out using a non-radiolabelled TNT reaction. Protein lysate (500 g) was diluted in NP-40 lysis buffer containing protease and phosphatase inhibitors (described below) and immunoprecipitated with 1 g of anti-FLT3 antibody (S-18) which recognizes all of the constructs containing a FLT3 portion. The immunoprecipitates were washed with wash buffer (10 mmol/l Tris-HCI, pH 7.4, 100 mmol/l NaCl, 0.1% Tween-20, 1 mmol/l dithiothreitol (DTT) and 10 g/ml aprotinin) and kinase buffer (10 mmol/l Tris-HCl, pH 7.4, 100 mmol/l NaCl, 0.1% Tween-20, 1 mmol/l DTT, 10 g/ml aprotinin, 10 mmol/l MnCl 2 and 10 mmol/l MgCl 2 ). Kinase reactions were carried out in 50 l of kinase buffer at 30°C for 20 min with the addition of 10 Ci of ␥ 32 P-ATP (6000 Ci/mmol, Amersham). Enolase (6 g) was also added as an exogenous substrate. The reactions were terminated by the addition of sample buffer followed by boiling for 5 min. The proteins were resolved by SDS-PAGE, transferred to Immobilon membrane and subjected to autoradiography or immunoblotting.
Cell culture and transfection
The murine IL-3-dependent pro-B cell line, Ba/F3, was maintained in RPMI 1640 medium (GIBCO) supplemented with 10% fetal calf serum (FCS; Gemini Bio-Products, Calabasas, CA, USA) and 1 ng/ml IL-3. Ba/F3 cells were transfected with vector, TEL (nucleotides 25-486), 49 FLT3, FLT3 (del), TEL-FLT3 and TEL-FLT3 (del) plasmid DNA by electroporation at 300 mV/960 F (Bio-Rad, Richmond, CA, USA). Transfected cells were cultured in IL-3 containing medium for 48 h and then selected in 1 mg/ml G418 (GIBCO) for a period of 2 weeks. The ability of the cells to survive in the absence of IL-3 was determined by trypan blue exclusion after plating aliquots of the washed cells in 96-well plates. Transfected cell lines were then subcloned by limiting dilution. For determination of growth properties of stably transfected Ba/F3 cells, G418-resistant cells were seeded at 8 × 10 4 cells per plate in medium in the presence or absence of 1 ng/ml IL-3. Viable cell numbers were counted from triplicate cultures at the indicated time intervals.
Cell starvation, stimulation and lysis
Parental and transfected Ba/F3 cells were washed free of residual IL-3 followed by cytokine deprivation for 16 h. Cells were then incubated with or without 1 ng/ml IL-3 or with or without 100 ng/ml FL for 15 min at 37°C under serum-free conditions. Cells were washed once in cold phosphate-buffered saline (PBS) and lysed in cold NP-40 lysis buffer containing protease and phosphatase inhibitors (2 mmol/l sodium orthovanadate, 50 g/ml antipain, 5 g/ml aprotinin, 1 g/ml leupeptin and 10 g/ml phenylmethylsulfonyl fluoride). Supernatants were collected after centrifugation at 16 000 g at 4°C and aliquots were used for immunoprecipitation with specific antibodies or boiled in sample buffer for later use as total cellular lysate.
Immunoprecipitation and immunoblotting
Clarified lysates were incubated for 16 h at 4°C with appropriate antibodies and then recombinant protein A-agarose (UBI) was added for 2 h at 4°C. Immunocomplexes were washed in TBST (10 mmol/l Tris-HCI, pH 7.4, 100 mmol/l NaCl and 0.1% Tween-20), TBS (10 mmol/l Tris-NaCl, pH 7.4 and 100 mmol/l NaCl), boiled in sample buffer, and resolved by SDS-PAGE. For immunoblotting, proteins were transferred to Immobilon membranes, blocked with 5% bovine serum albumin (BSA; Sigma, St Louis, MO, USA) in TBST and probed with specific primary antibodies. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibody (Amersham). The blots were then incubated with enhanced chemiluminescence ECL (Amersham) and exposed to film. In some cases, membranes were stripped of antibody for successive probing with different antibodies.
Mice and histopathology
Six-to 8-week-old Balb/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Animals were housed in a temperature/humidity controlled environment and fed commercial rodent chow and acidified water ad libitum. Mice (five in each group) were injected in a tail vein with 3 × 10 6 cells from the transfected Ba/F3 cell lines. Survival of the injected mice was monitored until day 50. Tissues from the sick mice including liver, spleen and bone marrow were subjected to histopathological examination. Complete necropsies were performed on mice at the Division of Comparative Medicine at the Johns Hopkins Hospital. Representative tissue samples were fixed by immersion in 10% neutral-buffered formalin, embedded in paraffin, and 5 m sections were stained with hematoxylin and eosin (H&E) and photographed with a Nikon microscope at 40-200 × magnification.
Results
Construction and oligomerization of chimeric receptors
Dimerization is known to be a prerequisite for activation of FLT3 and other receptor tyrosine kinases. 55 Previous studies have implicated the amino-terminal domain of TEL as responsible for the self-association and activation of the PDGF receptor portion of the fusion that results from the t(5;12) translocation that occurs between these two genes in a subset of CMML patients. 47, 48, 50 TEL-induced oligomerization has also been shown to induce constitutive activation of the protein kinase activity of non-receptor tyrosine kinases including ABL and JAK2. [52] [53] [54] To investigate whether fusion of FLT3 to the same domain of TEL would result in oligomerization and activation of FLT3, the HLH domain of TEL was fused to the cytoplasmic domain of the wild-type FLT3 receptor. The schematic illustration of the chimeric receptor and truncation mutant is shown in Figure 1a . In Figure 1b , total reaction products form the in vitro transcription and translation analysis confirmed that the fusions were of the expected size (lanes 1 and 2). Of note, all transcription and translation products containing TEL fusions showed doublets that are thought to result from an additional nearby in frame internal translation start site and have been reported previously. 51 To confirm the hypothesis that the TEL domain induces oligomerization of FLT3, the products were immunoprecipitated with FLT3 antibody specific for the carboxyl terminus of the FLT3 protein (Figure 1b, lanes 4-6) , or with IgG control (Figure 1b, lanes 7-9) . Because the TEL-FLT3 (del) does not contain the C-terminal epitope recognized by this antibody, the only way that it can be immunoprecipitated is by oligomerization with the full-length TEL-FLT3. The IgG control did not precipitate any of the translated proteins from the lysates (Figure 1b, lanes 7-9) . Antibody directed against the C-terminus of FLT3 immunoprecipitated the TEL- 
Constitutive activation of FLT3 by TEL
To investigate whether oligomerization of TEL-FLT3 would induce constitutive activation of the tyrosine kinase activity of the receptor in the absence of FLT3 ligand, constructs, including full-length FLT3, FLT3 (del), TEL, TEL-FLT3 and TEL-FLT3 (del), were in vitro transcribed and translated in the presence of non-radioactive methionine. The products were immunoLeukemia precipitated with anti-FLT3 antibody which recognizes the full-length and the kinase deletion constructs, and the precipitates were subjected to in vitro kinase reactions with 32 P-labelled ATP with the addition of enolase as an exogenous substrate. Immunoblotting analysis indicated that all proteins were expressed in the lysates (although at varying levels) and successfully immunoprecipitated (with the exception of TEL as expected, Figure 2, panel a) . Full-length FLT3, FLT3 (del) and TEL-FLT3 (del) proteins immunoprecipitated from the lysates did not exhibit tyrosine kinase activity (Figure 2, panel b,  lanes 2, 3 and 5) . This lack of kinase activity was seen even after 48 h of autoradiography. On the other hand, TEL-FLT3 immunoprecipitated from the lysate showed a high level of kinase activity, with only 30 min of exposure as measured by autophosphorylation of TEL-FLT3 protein and phosphorylation of added enolase substrate (Figure 2, panel b, lane 4) .
To examine whether TEL-FLT3 also becomes constitutively activated when expressed in a cell, we utilized the non-leukemic pro-B cell line, Ba/F3, derived from the Balb/c mouse. These cells do not express FLT3 receptor and are strictly dependent on IL-3 for survival and proliferation. Ba/F3 cells stably transfected with each of the constructs were used for preparing cell lysates. Lysates were immunoprecipitated using anti-FLT3 antibody followed by immunoblot analysis. The blots were probed sequentially with anti-phosphotyrosine antibody, stripped and then reprobed with anti-FLT3 antibody. Activation of TEL-FLT3 in vitro. Constructs were in vitro transcribed and translated with non-radioactive methionine and immunoprecipitated (IP) with an anti-FLT3 antibody that also recognizes deletion mutants. The immunoprecipitates were subjected to in vitro kinase assays using ␥-32 P ATP with enolase added as an exgenous substrate. The samples were analyzed by SDS-PAGE and the gel was cells. Since there was no addition of IL-3 to the cultures, the activation is independent of IL-3 stimulation.
Transforming activity of TEL-FLT3
To investigate the capacity of activated FLT3 to trigger a proliferative response, the growth properties of stably transfected Ba/F3 cells were examined. Transfected bulk Ba/F3 cell cultures were grown in the presence or absence of 1 ng/ml IL-3 for 6 days. Viable cell numbers were determined from triplicate cultures. In three separate experiments, all Ba/F3 transfectants grew at a comparable rate in the presence of IL- Figure 4a ). In contrast, when the transfectants were transferred to IL-3-deprived medium supplemented only with 10% FCS, cells transfected with vector alone, TEL, FLT3, FLT3 (del) and TEL-FLT3 (del) did not proliferate and all cells died within 4 days. Ba/F3 cells expressing TEL-FLT3, on the other hand, were capable of continuous proliferation in the absence of IL-3 at a rate comparable to parental or transfected cells grown in the presence of IL-3 ( Figure 4b ). These results demonstrate that constitutively activated FLT3 was able to abrogate IL-3 dependence and elicit a proliferative response in Ba/F3 cells. This IL-3-independent phenotype was not observed in cells expressing the kinase-deficient TEL-FLT3 (del). To examine the possibility of an autocrine mechanism evoked by TEL-FLT3 transfection, TEL-FLT3 expressing Ba/F3 cells were grown in IL-3-free medium and the conditioned medium was collected. Parental Ba/F3 cells were cultured in 10% FCS growth medium supplemented with 10-30% conditioned media in the absence of IL-3. Parental Ba/F3 cells did not proliferate and died rapidly, suggesting that autocrine production of IL-3 or other proliferative factors did not account for IL-3 independent growth of TEL-FLT3 expressing Ba/F3 cells (data not shown).
(
TEL-FLT3 expression induces constitutive tyrosine phosphorylation of cellular proteins in Ba/F3 cells
To compare the spectrum of intracellular substrates phosphorylated by constitutively activated TEL-FLT3 with that evoked by FL or IL-3 stimulation, parental Ba/F3 cells and cells expressing wild-type FLT3 or its kinase-deletion mutant FLT3 (del) were stimulated for 15 min with 100 ng/ml FL. Tyrosine-phosphorylated proteins were immunoprecipitated and then immunoblotted using antiphosphotyrosine antibodies. As illustrated in Figure 5 , FL elicited an increase in tyrosine phosphorylation of an array of proteins in FLT3 expressing Ba/F3 cells (lane 5). TEL-FLT3 expresses a similar increase of tyrosine phosphorylated proteins in a pattern very similar to that of FL stimulated FLT3 (compare lanes 5 and 8). Neither TEL-FLT3 (del) nor FL stimulated FLT3 (del) showed a similar pattern of phosphorylation.
Because TEL-FLT3 abrogated the requirement for IL-3, it was of interest to determine whether constitutive activation of FLT3 and activation of the IL-3 receptor resulted in phosphorylation of similar or distinct cellular substrates. Treatment of parental Ba/F3 cells with IL-3 resulted in phosphorylation of several prominent bands with some appearing similar but a number appearing different than the activated FLT3 pattern (compare lanes 2 to 5 or 8).
Participation of JAK and STAT proteins in FLT3-induced transformation
Given that binding of IL-3 to its cognate receptor induces tyrosine phosphorylation of proteins in the JAK-STAT signal transduction pathway 56, 57 and that the molecular masses of several prominent phosphoproteins in the lysate of TEL-FLT3 transfectant were similar to that of IL-3-treated parental cells,
Figure 5
Tyrosine phosphorylation of cellular proteins in Ba/F3 cells induced by constitutively activated TEL-FLT3. Parental Ba/F3 cells and stable transfectants grown in serum and IL-3-free medium for 16 h were incubated with or without murine IL-3 (1 ng/ml) or with or without FL (100 ng/ml). Whole cell lysates were prepared and subjected to immunoprecipitation (IP) with anti-phosphotyrosine anti Leukemia we examined the hypothesis that JAK-STAT proteins were tyrosine-phosphorylated following TEL-FLT3 activation in Ba/F3 cells.
In IL-3 responsive cells, JAK 1 and JAK 2 are phosphorylated rapidly on tyrosine residues upon stimulation by IL-3. To evaluate whether members of the JAK family were phosphorylated in TEL-FLT3 expressing Ba/F3 cells in the absence of IL-3, cell lystates were prepared and subjected to immunoprecipitation and immunoblotting with anti-JAK antibodies (Figure 6a ). As expected, both JAK 1 and JAK 2 were phos- 4 and 6) . In all transfected cells tested, there was no evidence of JAK 3 tyrosine phosphorylation although JAK3 protein was readily detectable (data not shown).
The STAT proteins are substrates of activated JAKs, 57 so it was of interest to determine whether any of these transcription factors were activated in TEL-FLT3 expressing Ba/F3 cells. (Figure 6b, lane 4) , suggesting partial activation in Ba/F3 cells. This slight activation could be due to the overexpression of FLT3 receptor on the cell surface resulting in clustering and spontaneous activation, residual FL in the medium, or a combination of the two. These results demonstrate that transformation of Ba/F3 to IL-3 independence by TEL-FLT3 was accompanied by constitutive phosphorylation of JAK 2, STAT 3, STAT 5a, STAT 5b and a 120 kDa polypeptide that coprecipitated with JAK 2.
Tyrosine phosphorylation of CBL in Ba/F3 cells expressing activated TEL-FLT3
CBL is a 120 kDa protein originally isolated as the cellular homolog of the product of the transforming oncogene v-cbl of the Cas NS-1 retrovirus. [58] [59] [60] Activation of v-cbl has been shown to induce pre-B cell lymphomas and myeloid leukemia in mice. Studies have shown that CBL is a target of tyrosine phosphorylation following cytokine stimulation by erythropoietin (EPO), IL-3 and FL among others. 24, 61 It is felt to modulate signaling pathways in cells by recruiting ubiquitin-conjugating enzymes to signaling substrates. 62 To investigate whether CBL was tyrosine-phosphorylated in response to constitutive activation of FLT3, CBL was immunoprecipitated from lysates of untreated or cytokine-treated parental and Ba/F3 transfectants, resolved by SDS-PAGE and immunoblotted consecutively with anti-phosphotyrosine and anti-CBL antibodies. As shown in Figure 7 , CBL was not phosphorylated in unstimulated cells (lanes 3-5, 7, 10), but was tyrosine phosphorylated after 15 min in response to IL-3 or FL stimulation (lanes 2 and 6). Notably, CBL was hyperphosphorylated in Ba/F3 cells expressing TEL-FLT3 (lane 9). The level of CBL phosphorylation varied much more than the level of CBL protein which also appeared to be slightly increased with stimulation ( Figure 7 , lower panel).
Leukemic potential of the constitutively activated FLT3 in mice
Because constitutively activated FLT3 conferred IL-3-independent growth on the transfected Ba/F3 cells, we investigated the leukemic potential of this cell line in syngeneic Balb/c mice. As illustrated in Figure 8 , transfected Ba/F3 cells expressing vector, TEL, FLT3 (del) or TEL-FLT3 (del) have no effect on the survival of the recipient mice over the experimental period of 50 days. In contrast, TEL-FLT3/BaF3 cellinjected mice became sick by 14 days following the injection and most died within 2-3 days after the onset of the illness with none surviving beyond 22 days post-inoculation. Surprisingly, inoculation of Ba/F3 cells expressing wild-type FLT3 also caused mortality in mice, although, with delayed mortality. This suggests that, as observed previously in cell culture, there was some degree of FLT3 activation in FLT3 expressing cells though this activation in vitro was not sufficient to cause Leukemia IL-3-independent growth under our culture conditions. Since mouse FLT3 ligand is known to be active on human FLT3 receptors, the FL-independent growth could be due to the combination of stimulation by FL expressed in the mice and overexpression of the receptor with subsequent self-association and activation.
Histopathological analysis of the vector/BaF3-control and TEL-FLT3/BaF3 inoculated mice revealed marked pathology in the latter group (Figure 9 ). Liver sections from the animals injected with vector/BaF3 cells demonstrated well-organized hepatic lobules (Figure 9a ). In the TEL-FLT3/BaF3 injected Leukemia mice, a massive infiltration of mononuclear cells was observed in the sinusoids of the liver (Figure 9b ). Mice transplanted with TEL-FLT3/BaF3 cells developed splenomegaly with splenic weights ranging from 0.70 to 1.1 g compared with control mice having an average of 0.15 g. Microscopic examination of the spleen from the control animals showed distinct white and red pulp with well-defined architecture (Figure 9c and e) . In contrast, the architecture of the spleen was almost completely effaced in TEL-FLT3/BaF3 inoculated mice (Figure 9d and f) . The splenic red pulp in these mice was extensively infiltrated by mononuclear cells with a lymphocytic appearance. The femoral head of TEL-FLT3/BaF3 inoculated mice were notable for increased cellularity in the marrow compartment and along the periosteum resulting from a massive mononuclear cell infiltration (Figure 9h) . The expansion and infiltration of mononuclear cells observed in liver, spleen and bone marrow of TEL-FLT3/BaF3 inoculated mice confirm a leukemic phenotype for the Ba/F3 cells expressing TEL-FLT3.
Discussion
FLT3 has been shown by our laboratory and a number of others to be overexpressed in most cases of B-lineage ALL and AML as well as in subsets of T cell ALL and CML in blast crisis. [28] [29] [30] [31] The overexpressed receptor is functional and can result in increased proliferation and block apoptosis in subsets of myeloid leukemia cells when stimulated with FL. 32 It has also been shown that mice in which FL is overexpressed are predisposed to the development of leukemia. 63 The internal tandem duplication of FLT3 that occurs in 20% of leukemic patients also appears to result in constitutive dimerization and activation. 46, 64 In order to study the possible effects of an activated FLT3 receptor and the signal transduction pathway induced by this activation, we generated a fusion of FLT3 with the oligomerization domain of TEL, analogous to the TEL-PDGF receptor fusion that occurs in CMML. Our results demonstrate that, when expressed in Ba/F3 cells, the TEL-FLT3 fusion was able to evoke a phosphorylation response similar to that elicited by the FL-stimulated wild-type FLT3. Furthermore, expression of TEL-FLT3 in Ba/F3 cells eliminated the IL-3 requirement for proliferation. These findings parallel previous observations that c-FMS/FLT3 chimeric receptors expressed in Ba/F3 cells were able to generate a proliferative response to CSF-1 in the absence of IL-3. 21, 22 We also detected a low level of wild-type FLT3 receptor activation in a ligand-independent manner in Ba/F3 cells expressing high levels of FLT3. Perhaps this is due to overexpression of surface receptor leading to spontaneous oligomerization and activation in the absence of ligand or to a sensitized response to small amounts of FL in serum.
The spectrum of tyrosine-phosphorylated proteins in TEL-FLT3 expressing cells partially overlaps that of parental Ba/F3 cells evoked by IL-3 stimulation. This was confirmed by immunoprecipitation and immunoblotting analyses of known components of the IL-3-mediated signaling cascade. In these studies, JAK 2, STAT 3, STAT 5a and STAT 5b were all found to be constitutively tyrosine-phosphorylated by the activated TEL-FLT3 as they are in IL-3 stimulated parental cells. This suggests that constitutively activated FLT3 might overcome the IL-3 dependence of the Ba/F3 cells by activating essential components of the IL-3 signaling pathway. There is some evidence for the coupling of JAK-STAT-mediated signaling to tyrosine kinase containing receptor activation. In these reports, JAK 1, JAK 2, STAT 1, STAT 3 and /or STAT 5 were tyrosine-phosphorylated following receptor activation in response to EGF, PDGF, CSF-1 or SCF stimulation. [65] [66] [67] [68] [69] [70] These studies, in conjunction with the findings reported here, imply a possible role for the JAK-STAT pathway in FLT3 receptor signaling. Whether this is a result of phosphorylation of JAKs by the activated receptor via a direct interaction of the two proteins or is indirect and results from phosphorylation and activation of other tyrosine kinases (eg SRC family members) or intermediate adaptor proteins is not known and will require further study.
Analysis of the substrate specificity of the FLT3 receptor in cell lines of myeloid and lymphoid origin has shown that the CBL proto-oncogene is prominently tyrosine-phosphorylated in response to FL stimulation. 24 CBL is also phosphorylated in response to a broad range of other cytokines including IL-2, IL-3, IL-15, GM-CSF, CSF-1 and EPO. 24, 61, 71, 72 It appears that CBL functions as an adapter protein to direct the ubiquitinmediated degradation of activated members of signaling pathways including RTKs and cytoplasmic kinases. In our experimental system, CBL was transiently tyrosine-phosphorylated in IL-3 stimulated parental and FL-stimulated, FLT3 expressing Ba/F3 cells, confirming the previous findings. 24, 73 Notably, CBL was constitutively hyperphosphorylated in cells expressing the TEL-FLT3 fusion. CBL is also constitutively phosphorylated in cells lines transformed with BCR-ABL. [74] [75] [76] Thus, CBL may play a role in TEL-FLT3-induced Ba/F3 cellular transformation. Alternatively, it could represent a heroic yet unsuccessful effort on the part of the cell to destroy the offending activated signaling protein(s).
Our animal studies show that there is a good correlation between the constitutive activation of FLT3 and leukemic development. Activating point mutations or chromosomal translocations involving FLT3 have not been reported thus far. However, internal tandem duplications of the juxtamembrane region of FLT3 gene reported in 20% of adult and childhood AML patients appears to constitutively activate the receptor. [42] [43] [44] [45] A recent publication has reported that 32D cells transfected with the mutated receptor are transformed and cause leukemia when injected into syngeneic mice. 77 The frequent overexpression of FLT3 seen in leukemias with the possibility of self-activation or heightened sensitivity to FL also makes the wild-type receptor a candidate for a potentially important role in this disease.
Taken together, our data provide evidence that an activated FLT3 can lead to leukemic transformation through constitutive activation of similar pathways utilized by FL-stimulated wildtype FLT3. This model should be useful in defining the critical elements of the pathway required for transformation and as a way to investigate possible therapeutic approaches in treating leukemia.
